Journey of Platelet Concentrates: A Review

Komal Saini, Priyanka Chopra and Vidushi Sheokand

Department of Periodontology, SGT University, Gurugram, India.
*Corresponding Author E-mail: drpriyankachopra79@gmail.com

http://dx.doi.org/10.13005/bpj/1875

(Received: 29 May 2019; accepted: 17 January 2020)

One of the important action of platelets is their role in haemostasis and healing of wound. Now they are gaining popularity in Dentistry in periodontal regeneration. Earlier fibrin glue was introduced as sealant, later the platelet-rich plasma (PRP); first generation of platelet concentrates was utilized in various fields of Dermatology from chronic ulcer management to trichology and also in aesthetics. Choukroun et al. in France in 2000’s introduced the second generation of platelet concentrates (PRF) Platelet Rich Fibrin. PRF have comparatively several advantages over traditionally prepared PRP. In this review we are focusing on why Platelet Concentrates are so important in Healing and Regeneration and we will also discuss the journey of fibrin glue from PRP to PRF, i-PRF, t-PRF, L-PRF etc.

Keywords: Platelet concentrates, PRP, PRF, and Wound Healing.

Periodontal repair and regeneration is the ultimate goal in treatment of Periodontal defects. Various biomaterials, natural as well as synthetic have been tried since many years to accelerate wound healing of both soft and hard tissue. Naturally occurring materials also known as “autologous biomaterials” are present in the body and provides signals for repair, regeneration and healing. Similarly, synthetically generated alloplastic materials have also shown promising result in many fields of regenerative dentistry but the drawback is that they may exhibit foreign body reaction. One of greatest disadvantage of synthetic materials considered for regeneration is that most of them are avascular in nature, to improve the acceptance the concentration of autologous biomaterials is increased to the wound site for enhancing healing. It has been noted that the bone graft material combined with blood is known to promote neo-angiogenesis, new bone formation when compared to bone grafts alone. Two important autologous biomaterials, platelets and fibrin are believed to play important role in promoting the healing of wound and regeneration.

Platelet concentrates had travelled a long way from introduction of platelet concentrates as a source of blood proteins enriched with growth factors to promote wound healing to introduction of fibrin glue, PRP, PRF, A-PRF, t-PRF, i-PRF, PRF lysates and CGF in recent years. Platelet concentrates used these days are very much efficient than predecessors in terms of biological efficacy and method of preparation.

Histologically diameter of platelets varies from 1 to 4 μm; they are colourless, non-nucleated with moderately refractive bodies. Precursor cell of
platelet are megakaryocytes, which are extremely large hematopoietic cells present in bone marrow. These megakaryocytes fragment into the small disc shape structures called platelets either in blood stream or in bone marrow itself; From where they squeeze through capillaries. Normal concentration of the platelets in blood is between 150,000 and 300,000 per mm$^3$. The average lifespan of a platelet is few days approximately 5 to 10 days. Spleen act as a reservoir for platelets, when needed released by sympathetically-induced contractions of splenic muscle.

Role of platelets in wound healing: A proinflammatory biochemical environment of wound impairs the healing affiliated to increased protease activity, which decreases the concentration of various Growth Factors (GFs). As a rich source of Growth Factors Platelet concentrates are used as an interesting alternative for the treatment for wounds and also have mitogenic, angiogenic, and chemotactic properties. Platelets exert its effects mainly due to three different granules namely $\alpha$ (alpha) granules, lysosomes and dense granules. These granules secretes the growth factors namely Platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), Fibroblast Growth Factor (FGF), Insulin like growth factor (ILGF), transforming growth factor (TGF) and epidermal growth factor (EGF). PDGF accelerates the wound healing because of the effect on mitosis, angiogenesis and promote the release of other growth factors. TGF play important role in promoting chemotaxis and along with the Insulin ILGF have role in activation of the Osteoblast. Platelets releases these growth factors within 10 min after clotting and approximately more than 95% of these presynthesized growth factor are released within first hour. When direct action of platelets diminish, macrophages arrives through vascular ingrowth stimulated by the platelets and then they become responsible for woundhealing regulation by secreting their own factors. So the platelets act as pace setter for wound healing.

**Chronological evolution of Platelet Concentrates**

The Journey starts from the development of platelet concentrates originating as key concept for fibrin adhesives development which were quite popular in 1970s in Europe. A list of various platelet concentrates evolved over the time is given in table 1.
In 1999 at the same time period, Anitua et al formulated another platelet concentrate utilizing anticoagulants and coined the term Platelet Rich Growth Factor (PRGF). These platelet concentrates were no longer in practice today because of lack of the specific pipetting steps, ergonomy of kit and the significant issues were present with this technique. Vivostat PRF (Alleroed, Denmark) a widely accepted technique for production of P-PRP was commercialized. However, it is misnamed as it is not a true PRF producing kit instead produces a PRP product. All the products were named as

<table>
<thead>
<tr>
<th>Sr No</th>
<th>Product Name and Year</th>
<th>Description/Technique</th>
<th>Drawbacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Platelet Concentrates as fibrin glue in 1970’s&lt;sup&gt;10&lt;/sup&gt;</td>
<td>Concentrated fibrinogen, factor XIII and fibronectin from donor plasma was mixed with thrombin and calcium which led to polymerization of fibrinogen</td>
<td>i. Risk of disease transmission due to commercially available products used in preparations</td>
</tr>
<tr>
<td>2</td>
<td>Autologous fibrin adhesive Tayapongsak 1994&lt;sup&gt;11&lt;/sup&gt;</td>
<td>Blood is collected one to three weeks before procedure followed by seprating of one unit of whole blood into RBC component and plasma fraction for using as cryo precipitates thawed 24 hours before being ready to use.</td>
<td>i. Technique was long and complex. ii. The amount of concentrate obtained was quite less as compared to the amount of blood collected. iii. Autologous fibrin sealants are generally weaker and have lower resistance than commercial sealants in terms of physical stress</td>
</tr>
<tr>
<td>3</td>
<td>Platelet rich Plasma (PRP) by Whitman 1997&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Double centrifugation of autologous blood is done consisted of a soft spin (1300 RPM -10 minutes) followed by a hard spin (2000 RPM -10 minutes) after that PRP collected at the bottom part of the tube.</td>
<td>i. Bovine thrombin which could give rise to life threatening coagulopathies in rare cases. ii. Higher concentration of thrombin may impede the cell migration during bone healing. iii. Release of growth factors from PRP over a short period of time.</td>
</tr>
<tr>
<td>4</td>
<td>Plasma rich growth Factors (PRGF) Anitua &amp; co-workers 1999&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Venous blood collected in several test tubes with anticoagulant and centrifuged at 460G for 8 mins, resulted in collection of plasma rich growth factors (PRGF) at the bottom of the tube. This PRGF was then taken from the bottom of the tubes and caco&lt;sub&gt;3&lt;/sub&gt; is added (0.05ml/ml of PRGF). This led to coagulation in around 10 minutes and a gelatinous PRGF is obtained</td>
<td>i. Incomplete activation of platelets and low levels of growth factors release.</td>
</tr>
<tr>
<td>5</td>
<td>Platelet Rich Fibrin (PRF) Choukron et al 2001&lt;sup&gt;14&lt;/sup&gt;</td>
<td>10 ml of blood sample without anticoagulant is centrifuged at approximately 400 g (3000 rpm -10 min).</td>
<td>i. Limited amount of PRF obtained from an autologous blood sample, the quantities produced are low. ii. The systematic utilization of PRF for general surgery is limited.</td>
</tr>
</tbody>
</table>
Platelet rich plasma (PRP) or also known as first generation of platelet concentrate.\textsuperscript{20} Platelet Rich Gel (PRG) proposed to be more active than PRP by Cieslik-Bielecka\textsuperscript{21} and they defined it as fibrin matrix rich in platelets, leukocytes and relative active molecule which is biologically more activated. Sacco\textsuperscript{22} in 2006 give a new concept of concentrated growth factors. Preparation of concentrated growth factor required venous blood with rpm in range of 2400-2700. Sacco’s membrane shows a complex three-dimensional architecture which makes it’s a biomaterial rich in fibrin, platelets, leukocytes and growth factors very suitable for both patients and

<table>
<thead>
<tr>
<th>Advancement in PRF Technology</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Platelet Rich Fibrin (A-PRF) by Ghanaati in 2014\textsuperscript{10}</td>
<td>1500 RPM for 14 minutes in sterile plain glass based vaccume tubes</td>
</tr>
<tr>
<td>Advanced Platelet Rich Fibrin+ (A-PRF+) by Fujoka-kobayashi in 2016\textsuperscript{11}</td>
<td>1300 RPM for 8 minutes in sterile plain glass based vaccume tubes</td>
</tr>
<tr>
<td>Injectable Platelet Rich Fibrin (i-PRF) by Mourao in 2015\textsuperscript{12}</td>
<td>700 RPM for 3 minutes in plastic tubes</td>
</tr>
<tr>
<td>Titanium – platelet rich fibrin (T-PRF) Tunali and co-worker 2014\textsuperscript{26}</td>
<td>2800 RPM for 12 minutes in medical grade Titanium Tubes</td>
</tr>
</tbody>
</table>

Fig. 1. Steps in preparation of Platelet Rich Plasma by Double Centrifugation\textsuperscript{26}
doctor. One of the complication associated with PRP handling is its liquid nature, which reduce its application as it required in combination with other biomaterials. The clinical benefits with PRP is limited because of short release of growth factors. Due to this limitation second-generation platelet concentrate termed PRF have been emerged. In 2000 Choukroun et al14 introduced Platelet rich fibrin labelled as PRF, based on the strong fibrin gel polymerization which is another form of Platelet concentrate in France. This is an important turnaround in the evolution of terminology.

According to Everts et al23 platelet concentrates has been found in two forms, which include nonactivated and activated forms (on the basis of leukocyte component). The inactivated form was called "platelet-leukocyte rich plasma (P-LRP) and the activated form was called platelet-leukocyte-gel" (PLG). In 2010 by Sohn24 concept of sticky bone was introduced in which autologous fibrin glue was mixed with bone graft. Later on, APRF (advanced PRF) introduced in 2014 by Choukroun et al which contain more monocytes.25 Later Titanium prepared PRF (T-PRF) by Tunali et al26 introduced. In 2015 Mourao et al27 gave detailed information on preparation of i-PRF (injectable PRF).

**Protocol of PRF Preparations and its Advancement**

Dr. Joseph Choukroun the research pioneer has led to the development of a second-generation platelet concentrate, in this anticoagulation factors have not been utilized. A platelet concentrate without coagulation factors can be gathered (750 g) from the superficial layer of centrifugation tubes following single centrifugation cycle (2,700 rpm, 12 minutes). This formulation was called Platelet rich fibrin and it contained a fibrin matrix after centrifugation. The composition of PRF include concentrate of white blood cells, platelets, and fibrin. It has been shown that the initially developed Platelet rich fibrin (also termed L-PRF) composed of 97% platelets and more than 50% leukocytes in a high-density fibrin network when compared to whole blood.28

The major drawback of PRF is its preparation along with storage. The factor affecting the potential benefit of PRF includes its quick handling between the blood collection and the centrifugation as PRF preparation does not include any anticoagulants. One of the other important benefit include the dehydration which cause decreased growth factor content in PRF and leukocyte viability will be adversely affected altered its biologic properties. Platelet rich fibrin is obtained as a gel form which is not conducive to be injected. To overcome these limitations several modifications are done and newer forms of PRF were introduced.29

Later the advanced PRF matrices in solid form was developed having the (LSCC) Low Speed Centrifugation Concept. This improved preparation protocol for advanced PRF (A-PRF) is reducing the applied RCF to 208 g. The structure of advanced fibrin clot is a more porous with a larger interfibrous space when compared to PRF. For formation of A-PRF, slower speed (1500 rpm) and more time (14 mins) is used in the sterile plain glass-based vacuum tubes.30

A-PRF shows more neutrophilic granules in distal part mostly at red blood cells-buffer coat interface. Another modification of A-PRF has been suggested by Kobayashi & co-workers in 2016 where they have reduced the centrifugation time to 1300 rpm for 8 minutes. They called this modification as A-PRF+ and suggested that less time would result in a decrease in the amount of forces that the cells of the blood would be exposed to & hence, would increase the number of cells contained in the PRF matrix.31

The PRF so obtained is in gel form which is not conducive to be injected. To overcome this limitation i-PRF is introduced. For producing i-PRF, blood is drawn without anticoagulant in plastic tubes without any coatings and centrifuged at around 700 for 3 minutes.27 The time is considerably shorter than other two protocols (i.e. L-PRF & A-PRF). This can be attributed to the fact that for i-PRF only the separation of blood components is desired which happens in initial 2-4 minutes. Plastic tubes are used for this process as it have a hydrophobic surface and do not efficiently activate the coagulation process. Hence, all the blood components that are required to form a good platelet concentrate (plasma containing all clotting factors & platelets) reach the top of the tube under the centrifugation force in the first 2-4 minutes. Currently, it has been used for mixing with bone grafts, which forms a gel-putty consistency with the graft particles incorporated in the graft. The graft
thus formed has a good workable consistency, leads to decreased leaching of the graft as it is tightly encapsulated in the fibrin matrix. Another modification of PRF is T-PRF, i.e. Titanium -PRF, obtained by centrifugation of blood at 2800 RPM for 12 minutes in Titanium tubes. T-PRF provide more tightly woven and thicker fibrin than classic L-PRF, as has titanium better hemocompatibility compared to glass and potentially led to the formation of a more polymerized fibrin.

CONCLUSION

Platelet concentrates has been used in various application of dentistry since many years. Technological advancement in this field shows promising result in use of platelet rich fibrin (PRF) in Periodontal regeneration. Various studies have been conducted to determine the utilization of PRF in various procedures i.e periodontology, oral surgery, and implant dentistry and encouraging results obtained in both soft and hard tissue regeneration. Various factors like speed, duration of centrifuge, temperature, blood haematocrit influence the quality of fibrin scaffold. Lastly, the prominent role of leukocytes or fibrin in PRF scaffolds is discussed as potential avenues for future research.

ACKNOWLEDGEMENT

I express my profound sense of gratitude and sincere regards to Dr. Priyanka Chopra and Dr. Vidushi Sheokand for their meticulous supervision, valuable guidance, encouragement, and critical appreciation. I would also like to thank my husband Maj (Dr) Sachin Saini, my little daughter Vedika and all family members for their unconditional love and support during this work.

REFERENCES

17. Rosenthal AR, Egbert PR, Harbury C, Hopkins JL, Rubenstein E. Use of platelet-fibrinogen-


